Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2007

Laureate Pharma to Manufacture Trubion’s Cancer Candidate

  • Laureate Pharma will produce Trubion Pharmaceuticals’ non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) drug candidate. TRU-016 targets CD37, an antigen present on B cells.

    The company expects to file an IND for TRU-016 in the second half of 2007 after completing preclinical testing.
    Trubion currently retains all development and commercialization rights for the TRU-016 program.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »